trending Market Intelligence /marketintelligence/en/news-insights/trending/9G72IhZuA1BUsTJ-MDsolA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Forty Seven prices $170.1M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Forty Seven prices $170.1M common stock offering

Forty Seven Inc. priced its public offering of 4,860,000 common shares at $35 per share.

The Menlo Park, Calif.-based immuno-oncology company also granted underwriters a 30-day option to buy up to an additional 729,000 common shares at the same price.

Gross proceeds are expected to be $170.1 million.

The offering is expected to close Dec. 16.

Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC are joint book-running managers for the offering, while Guggenheim Securities LLC and Oppenheimer & Co. Inc. are acting as lead managers. JonesTrading Institutional Services LLC and Roth Capital Partners LLC are co-managers.

Forty Seven develops therapies for cancer. Its blood cancer therapy magrolimab was granted fast-track designation by the U.S. Food and Drug Administration in September.